EA200600998A1 - Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза - Google Patents

Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза

Info

Publication number
EA200600998A1
EA200600998A1 EA200600998A EA200600998A EA200600998A1 EA 200600998 A1 EA200600998 A1 EA 200600998A1 EA 200600998 A EA200600998 A EA 200600998A EA 200600998 A EA200600998 A EA 200600998A EA 200600998 A1 EA200600998 A1 EA 200600998A1
Authority
EA
Eurasian Patent Office
Prior art keywords
zinc
treatment
complex
pharmaceutical composition
hyaluronane
Prior art date
Application number
EA200600998A
Other languages
English (en)
Other versions
EA009209B1 (ru
Inventor
Дьёрдь Тибор Балог
Янош Иллеш
Андраш Борош
Габорне Форрай
Акошне Секей
Original Assignee
Рихтер Гедеон Ведьесети Дьяр Рт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рихтер Гедеон Ведьесети Дьяр Рт. filed Critical Рихтер Гедеон Ведьесети Дьяр Рт.
Publication of EA200600998A1 publication Critical patent/EA200600998A1/ru
Publication of EA009209B1 publication Critical patent/EA009209B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к фармацевтическим композициям для лечения рассеянного склероза, которые включают в качестве активного ингредиента цинк-гиалуронановый комплекс, предпочтительно цинк-гиалуронановый комплекс с молекулярной массой 800-1200 кДа и фармацевтически применимый носитель и/или добавку. Область изобретения также охватывает способ получения указанной фармацевтической композиции, а также ее терапевтическое применение для лечения рассеянного склероза.
EA200600998A 2003-11-20 2004-11-18 Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза EA009209B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0303779A HUP0303779A2 (en) 2003-11-20 2003-11-20 Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
PCT/HU2004/000107 WO2005049047A1 (en) 2003-11-20 2004-11-18 Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
EA200600998A1 true EA200600998A1 (ru) 2006-10-27
EA009209B1 EA009209B1 (ru) 2007-12-28

Family

ID=90001707

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600998A EA009209B1 (ru) 2003-11-20 2004-11-18 Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза

Country Status (20)

Country Link
US (1) US20070123488A1 (ru)
EP (1) EP1699468B1 (ru)
JP (1) JP4778908B2 (ru)
CN (1) CN1882352B (ru)
AT (1) ATE359800T1 (ru)
CY (1) CY1106617T1 (ru)
DE (1) DE602004006024T2 (ru)
DK (1) DK1699468T3 (ru)
EA (1) EA009209B1 (ru)
ES (1) ES2286698T3 (ru)
HK (1) HK1098352A1 (ru)
HR (1) HRP20070291T3 (ru)
HU (1) HUP0303779A2 (ru)
NO (1) NO336121B1 (ru)
PL (1) PL1699468T3 (ru)
PT (1) PT1699468E (ru)
RS (2) RS50523B (ru)
SI (1) SI1699468T1 (ru)
UA (1) UA83516C2 (ru)
WO (1) WO2005049047A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007153761A (ja) * 2005-12-01 2007-06-21 Toshitsu Kagaku Kenkyusho:Kk シナプス伝達促進剤及びシナプス保護剤
US20070099867A1 (en) * 2005-05-24 2007-05-03 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
NO20064337L (no) * 2005-09-26 2007-03-27 Glycoscience Lab Inc Farmasoytisk middel inneholdende hyaluronan som en aktiv ingrediens
JP2009091248A (ja) * 2006-01-17 2009-04-30 Toshitsu Kagaku Kenkyusho:Kk 外傷性神経障害および／または運動機能障害の治療薬
CN101389342B (zh) 2006-12-05 2012-08-08 株式会社糖质科学研究所 用于变性关节炎的治疗剂
JP2007277258A (ja) * 2007-06-20 2007-10-25 Toshitsu Kagaku Kenkyusho:Kk 炎症及び神経疾患の治療剤及び予防剤
US8399413B2 (en) * 2009-08-20 2013-03-19 Yeda Research & Development Co., Ltd. Low frequency glatiramer acetate therapy
CN111647100B (zh) * 2020-07-14 2022-03-01 山东华熙海御生物医药有限公司 一种高分子量透明质酸锌的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203372B (en) * 1989-02-24 1991-07-29 Richter Gedeon Vegyeszet Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
KR100294060B1 (ko) * 1995-09-28 2001-08-07 데이비드 엘. 윈터 면역억제제로서히알루론산을이용하는방법
HU225991B1 (en) * 1997-04-29 2008-02-28 Richter Gedeon Nyrt Use of the zinc hyaluronate associate (complex) for the preparation of pharmaceutical compositions for oral use against peptic ulcer
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
JP2003089647A (ja) * 1999-03-10 2003-03-28 Takada Seiyaku Kk 関節性疾患治療剤
JP2001163789A (ja) * 1999-12-13 2001-06-19 Maruho Co Ltd マトリックスメタロプロテアーゼ阻害用医薬組成物
BG104880A (en) * 2000-10-24 2002-04-30 Иван ХРИСТОВ Medicamentous preparation for multiple sclerosis treatment
US20040097465A1 (en) * 2001-03-15 2004-05-20 Akira Asari ll-12 expression controlling agents

Also Published As

Publication number Publication date
CY1106617T1 (el) 2012-01-25
CN1882352B (zh) 2010-08-04
ATE359800T1 (de) 2007-05-15
RS50523B (sr) 2010-05-07
UA83516C2 (ru) 2008-07-25
NO336121B1 (no) 2015-05-18
HUP0303779D0 (en) 2004-03-01
NO20062857L (no) 2006-08-18
SI1699468T1 (sl) 2007-08-31
EP1699468B1 (en) 2007-04-18
PL1699468T3 (pl) 2007-09-28
JP2007512311A (ja) 2007-05-17
DE602004006024D1 (de) 2007-05-31
CN1882352A (zh) 2006-12-20
EP1699468A1 (en) 2006-09-13
WO2005049047A1 (en) 2005-06-02
ES2286698T3 (es) 2007-12-01
DK1699468T3 (da) 2007-09-03
PT1699468E (pt) 2007-06-05
JP4778908B2 (ja) 2011-09-21
HRP20070291T3 (en) 2007-10-31
DE602004006024T2 (de) 2007-12-27
US20070123488A1 (en) 2007-05-31
RS20060325A (en) 2008-08-07
HK1098352A1 (en) 2007-07-20
HUP0303779A2 (en) 2006-02-28
EA009209B1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
EA200701296A1 (ru) 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
MY143795A (en) Tetrahydropyridoindole derivatives
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
TW200611695A (en) Pyrrolopyridine derivatives
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
EA200801711A1 (ru) Пролекарства возбуждающих аминокислот
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
TW200639159A (en) Treatment of pain
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
EA200401526A1 (ru) Новые соединения и их применение
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
HK1098352A1 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
SE0402925D0 (sv) Novel Compounds
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
EA200700403A1 (ru) ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU